Connect with us

Healthcare

Natco Pharma Limited Receives Positive FDA Inspection Report for Visakhapatnam Plant

Natco Pharma Limited (NSE: NATCOPHARM) receives positive FDA inspection report for Visakhapatnam plant, classifying it as Voluntary Action Indicated (VAI).

Shruti singh - TradeAlone

Published

on

Natco Pharma Limited Natcopharm Positive FDA Inspection

Natco Pharma Limited (NSE: NATCOPHARM) announced today the receipt of a positive Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its Visakhapatnam plant. The inspection, conducted from August 17th to August 21st, 2026, resulted in the classification of the inspection as Voluntary Action Indicated (VAI), indicating minor observations. The company received four observations in the Form 483 during the inspection.

Positive Outcome

The positive outcome of the FDA inspection is a significant milestone for Natco Pharma Limited, reinforcing the company’s commitment to maintaining high standards in its manufacturing processes. The classification as VAI suggests that while there are minor areas for improvement, the overall compliance with regulatory standards is satisfactory.

Commitment to Quality

Natco Pharma Limited continues to prioritize quality and regulatory compliance in its operations. The company’s manufacturing facilities are approved by several leading regulatory authorities, including the U.S. FDA, Brazil ANVISA, Health Canada, and WHO, serving over 50 global markets. The positive FDA report further solidifies the company’s reputation for producing high-quality pharmaceuticals.

Natco Pharma Limited remains dedicated to its mission of developing, manufacturing, and distributing generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients, and crop protection products. The company’s R&D-oriented approach and science-driven focus enable it to lead in targeted therapies, particularly in oncology, both domestically and internationally.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Natco Pharma Limited

Natco Pharma Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

NATCOPHARM
Healthcare › Drug Manufacturers - Specialty & Generic
APPROACHING RESISTANCE
80
Fundamental
66
Technical
73
Overall

1W +1.63%
1M +2.63%
3M -7.63%
P/E: 17.9 Cap: Mid
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Natco trades in the lower quarter of its 52-week range. The PEG of 0.70 signals undervaluation relative to growth. It is a potential re-rating candidate. Industry-leading margins of 26.8% reflect exceptional pricing power and operational efficiency. Buyers show up with 1.9x the volume of sellers. Moreover, they dominated on 16 of recent sessions versus 14 for sellers — a healthy accumulation pattern. Revenue grows at 14.5% and profits at 25.6% CAGR, with D/E of 0.03. Meanwhile, the stock dips 7.6% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Natco Pharma Limited.

BETA

Beta Drugs Limited Forms Oncology Joint Venture with IMGSA Groupe SPA

Beta Drugs Limited forms oncology joint venture with IMGSA Groupe SPA, acquiring oncology plant for US$8.7 million.

adit chauhan author tradealone

Published

on

Beta Drugs Limited BETA Oncology JV IMGSA

Beta Drugs Limited (“Beta”) today announced that it has entered into a joint venture (“JV”) with IMGSA Groupe SPA (“IMGSA”), a leading pharmaceutical company in Algeria. Beta will hold a 49% stake in the JV, acquiring IMGSA’s oncology formulation plant for US$8.7 million. This strategic move aims to deepen the partnership and build a strong oncology business in Algeria and North African markets.

Transaction Details

The JV will acquire the oncology plant from IMGSA for US$8.7 million. Part of the consideration will be settled by issuing equity shares to IMGSA. Beta will infuse US$3 million over three years and transfer formulation technology to the JV. The plant has manufacturing capabilities for both injectable and oral solid dosage forms, enabling the JV to produce a range of oncology products locally in Algeria.

Market Positioning

The Algerian oncology market is valued at approximately US$1 billion and growing rapidly. The JV is well positioned to capture significant market share in national tenders by combining Beta’s research, development, manufacturing, and supply chain capabilities with IMGSA’s marketing and distribution infrastructure. The Algerian government incentivizes local manufacturing of critical life-saving pharmaceutical products, further supporting the JV’s growth.

Rahul Batra, MD of Beta Drugs Limited, said: “Our relationship with IMGSA has grown steadily over many years, and this joint venture marks a natural next step for us to deepen our relationship and commitment to the Algerian market. By bringing our manufacturing technology and know-how to a well-equipped oncology plant and pairing it with IMGSA’s strong market presence in Algeria, we aim to improve access to quality cancer therapies for patients in Algeria.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Beta Drugs Limited

Beta Drugs Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

BETA
Healthcare › Drug Manufacturers - Specialty & Generic
CONSOLIDATING DOWN
60
Fundamental
66
Technical
64
Overall

1W -4.04%
1M +2.59%
3M -27.49%
P/E: 36.2 Cap: Small
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Beta falls 25.9% over three months and has not found a floor yet. The PEG reaches 3.48. The stock trades on brand and index weight, not on growth. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gains 4.8% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 19.2% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Beta Drugs Limited.

Continue Reading

Health Information Services

Indegene Limited (indgn) Becomes First Industry Partner of Indo-uk Life Science Corridor

Indegene Limited (INDGN) announced as the first industry partner for the Indo-UK Life Science Corridor, connecting India and UK research.

preety tomer tradealone

Published

on

Indegene Limited INDGN First Industry Partner Indo-uk Life Science Corridor

Indegene Limited (INDGN) has been announced as the first industry partner for the Indo-UK Life Science Corridor, a collaboration between the Centre for Cellular and Molecular Platforms (C-CAMP) and Imperial College London. This initiative, supported by the Imperial Global India initiative, aims to connect world-class research in India and the UK with entrepreneurship, industry expertise, and pathways to translation. The corridor is designed to facilitate the two-way sharing of knowledge and evidence on priority challenges, innovation readiness, and ecosystem needs.

Strategic Collaboration

Indegene, C-CAMP, and Imperial College London will co-develop entrepreneurship programs and support the exchange of knowledge and talent between India and the UK. Indegene, an AI-native operating partner for modern life sciences, brings deep industry context to the corridor and has a track record of working with the world’s top 20 biopharma companies. As part of the collaboration, Indegene will help define industry challenges and support startup exchanges and ecosystem immersion programs.

Focus Areas

Initial focus areas include antimicrobial resistance, diagnostics, digital health, agritech, brain science, and mental health. The three organizations made the announcement at the C-CAMP–Imperial joint Roundtable on International Partnerships for AI Discovery and Innovation, convened under the Government of Karnataka’s Global Innovation Alliance initiative as part of the Bengaluru Tech Summit 2026.

The partnership reflects Indegene’s commitment to support deep science, strengthen translation pathways, and help promising innovation reach scale. This collaboration is expected to produce smarter, more scalable, and more accessible innovations relevant to both populations.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Indegene Limited

Indegene Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

INDGN
Healthcare › Health Information Services
BREAKOUT
62
Fundamental
80
Technical
71
Overall

1W -3.1%
1M +9.71%
3M +14.89%
P/E: 38 Cap: Mid
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Indegene gains 15.9% over three months and trades near its 52-week highs. The PEG of 2.41 makes it expensive versus peers. The premium needs earnings to catch up quickly. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gives back 2.0% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The stock rises 15.9% in three months on 15.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Indegene Limited.

Continue Reading

BIOCON

Biocon Limited (biocon) Secures Marketing Authorization for Pertuzumab in EU

Biocon Limited (BIOCON) secures EU marketing authorization for Pertuzumab, its first biosimilar under new clinical approach.

abhinav tiwari

Published

on

Biocon Limited Biocon November 2026 Event

Biocon Limited (BSE: 532523; NSE: BIOCON) has announced that the European Commission (EC) has granted marketing authorization for Pebrilzo®, its biosimilar pertuzumab, for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union (EU). This marks a significant regulatory milestone for Biocon, as pertuzumab becomes its fifth oncology biosimilar approved in both Europe and the United States, strengthening its global oncology portfolio.

First Biosimilar Under New Clinical Approach

Biocon’s pertuzumab biosimilar is the first biosimilar to receive EC marketing authorization under the European Medicines Agency’s (EMA) new tailored clinical approach. This milestone follows its positive CHMP opinion on September 17, 2026. Shreehas Tambe, CEO & Managing Director, Biocon, said: “The European Commission’s approval of Pebrilzo®, our pertuzumab biosimilar, the first under its new tailored clinical pathway, marks a significant regulatory milestone for Biocon. With this approval, pertuzumab becomes our fifth oncology biosimilar approved in both Europe and the United States, strengthening our global oncology portfolio and reinforcing our commitment to expanding access to high-quality, affordable biologic therapies for patients with HER2-positive breast cancer.”

Broadening Treatment Options

The approval aims to broaden treatment options for patients with HER2-positive breast cancer while supporting more sustainable healthcare systems in Europe. Extensive orthogonal, state-of-the-art structural and functional analytical characterization, together with comparative clinical pharmacokinetic data, demonstrated that Biocon’s pertuzumab biosimilar is highly similar to the reference product, with no clinically meaningful differences in quality, safety, or efficacy.

As Biocon continues to expand its portfolio and commitment to oncology, this approval underscores its dedication to addressing evolving patient and healthcare needs, particularly in the realm of breast cancer treatment.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

BIOCON
Healthcare › Biotechnology
APPROACHING RESISTANCE
52
Fundamental
60
Technical
56
Overall

1W -1.97%
1M +6.96%
3M -11.74%
P/E: 122 Cap: Large
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Biocon falls 12.8% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gains 2.9% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.

Continue Reading

Trending